• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

SonaCare Medical

FDA clears next-gen Sonablate prostate device from SonaCare

January 11, 2017 By Sarah Faulkner

SonaCare Medical said today that it won 510(k) approval from the FDA for the latest version of its high intensity focused ultrasound prostate tissue ablation device. The Sonablate device was the 1st of its kind to receive regulatory approval for the focused ablation of prostate tissue, according to SonaCare. The next-gen version features a tool […]

Filed Under: 510(k), Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Ultrasound Tagged With: SonaCare Medical

SonaCare inks marketing deal with Philips’ Invivo biz for its UroNav software

May 5, 2016 By Fink Densford

SonaCare Medical said today it inked a marketing alliance deal with Royal Philips (NYSE:PHG) business Invivo to license its UroNav fusion software with its Sonablate planning system. The new deal will allow clinicians to use the UroNav device to annotate and biopsy targeted prostate tissue and localize the tissue appropriate for ablation directly with its […]

Filed Under: Business/Financial News, Urology Tagged With: InVivo Therapeutics, Philips, SonaCare Medical

FDA clears Edap’s Ablatherm prostate device

November 9, 2015 By Brad Perriello

Edap (NSDQ:EDAP) said today that it won 510(k) clearance from the FDA for its Ablatherm, less than a month after a similar device from rival SonaCare won a nod from the federal safety watchdog. The Ablatherm device, like SonaCare’s Sonablate 450, is designed to ablate prostate tissue using high-intensity focused ultrasound. After a years-long dance with the FDA that […]

Filed Under: Food & Drug Administration (FDA), Radiosurgery/Radiation therapy, Regulatory/Compliance, Urology Tagged With: EDAP TMS SA, SonaCare Medical

FDA clears SonaCare HIFU prostate device, prompts Edap to yank de novo, go for 510k

October 15, 2015 By Fink Densford

SonaCare said it won FDA pre market approval for its high intensity focused ultrasound device designed to treat prostate cancer, causing competitor EDAP (NSDQ:EDAP) to yank the de novo application for its Ablatherm HIFU. SonaCare said its Sonablate 450 will be available in the U.S. this October. “The FDA regulatory authorization to market Sonablate in the […]

Filed Under: Food & Drug Administration (FDA), Oncology, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: EDAP TMS SA, SonaCare Medical

Prostate cancer: FDA panel recommends against approval for SonaCare’s Sonablate

October 6, 2014 By Alexander Soule Leave a Comment

Prostate cancer: FDA panel recommends against approval for SonaCare's Sonablate

SonaCare Medical said it will reposition its Sonablate prostate cancer device to treat a more aggressive stage of the disease after an FDA panel last week failed to recommend approval for the device.

Filed Under: Food & Drug Administration (FDA), News Well, Urology Tagged With: SonaCare Medical

SonaCare lands a date with the FDA for prostate cancer therapy

August 6, 2014 By Arezu Sarvestani Leave a Comment

SonaCare lands a date with the FDA for prostate cancer therapy

North Carolina-based SonaCare Medical is getting a day with the FDA, but the company’s prospects are murky given that it’s going before an advisory panel that just rejected a technology similar to SonaCare’s Sonablate 450 prostate cancer therapy.

Filed Under: News Well, Pre-Market Approval (PMA), Regulatory/Compliance, Urology Tagged With: Ablation, Prostate, SonaCare Medical

Cardiovascular Systems prices $33M offering | Wall Street Beat

March 20, 2013 By Brad Perriello Leave a Comment

MassDevice.com Wall Street Beat

Cardiovascular Systems (NSDQ:CSII) priced a public offering of some 2 million shares of CSII stock at $17.60 apiece, saying it expects to net about $33 million from the deal.

Filed Under: Cardiovascular, Funding Roundup, News Well, Wall Street Beat Tagged With: Cardiovascular Systems Inc., Gamma Medica, Imaging Acquisitions, Kips Bay Medical Inc., Minnesota, SonaCare Medical, US HIFU, Zeo Inc.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS